Compare Procter & Gamble Co (PG) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs BIO-TECHNE Corp — how do they compare? Procter & Gamble Co trades at $150.55 (market cap $343.34B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: Procter & Gamble Co is far larger — about 30.2× BIO-TECHNE Corp's market cap, and Procter & Gamble Co pays the higher dividend (2.95%). Which is the better fit depends on your goals — on Pluang, investors hold Procter & Gamble Co for 131 Days and BIO-TECHNE Corp for 63 Days on average.
| PG | TECH | |
|---|---|---|
Market Cap | $343.34B | $11.37B |
Volume | 8,662,344 | 3,153,511 |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $72.61 |
52-Week Low | $138.10 | $43.31 |
Typical Hold Time | 131 Days | 63 Days |
Enterprise Value | $369.18B | $11.40B |
Dividend Yield | 2.95% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $150.59, up 1.47% today, with a bullish technical signal from moving averages and a consensus analyst price target of $160.13. The company reported revenue of $84.28 billion in 2025, with net income of $15.97 billion and strong profitability margins. Recent earnings have consistently beaten expectations, and the stock offers a dividend yield with a history of increases.
PG presents a stable investment with consistent earnings and dividend growth, supported by a robust balance sheet. Risks include premium valuation multiples and modest revenue growth outlook. Analyst sentiment is predominantly positive, with 53% buy ratings, but investors should monitor competitive pressures and economic sensitivity.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
